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Background. Medical therapy for secondary hyperparathy-
roidism (SHPTH) has evolved considerably during the past
decade. It is not known how changes in medical therapy might
impact the parathyroidectomy (PTX) rate among dialysis pa-
tients. Relatively low parathyroid hormone (PTH) levels have
been found among elderly dialysis patients and those with
diabetes. Clinical factors associated with differing PTX rates
among United States dialysis patients have not been reported.
We report PTX rates in the United States from 1990 to 1999
among persons with end-stage renal disease, accounting for
changes in patient characteristics.
Methods. Data from the United States Renal Database were
utilized. Patients insured by Medicare or Medicaid and receiv-
ing renal replacement therapy between January 1, 1990, and
December 31, 1999 were considered for analysis. PTX was de-
termined by ICD-9 procedure codes. Multivariate Poisson mod-
els were used to estimate adjusted PTX rates.
Results. The overall observed PTX rate in the study sam-
ple was 7.16 per 1000 person-years at risk. After a slight rise
during the early 1990s, adjusted PTX rates declined by approx-
imately 30% between 1995 and 1999. Adjusted PTX rates were
higher among patients who were younger, female, nondiabetic,
receiving peritoneal dialysis, and those with a longer cumulative
duration of dialysis.
Conclusion. PTX rates have recently decreased in the United
States, independent of changes in patient characteristics. The
effectiveness of medical therapy in targeting secondary hy-
perparathyroidism may be improving. Younger, nondiabetic
patients with a longer cumulative dialysis burden are at par-
ticularly high risk for PTX.
Secondary hyperparathyroidism (SHPTH) is highly
prevalent among patients with end-stage renal disease
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(ESRD) [1]. Historically, SHPTH has been linked to ure-
mic bone disease [2, 3]. More recently, derangements
of parathyroid hormone (PTH), calcium, and phosphate
metabolism have been associated with vascular calcifica-
tion and cardiovascular death among persons with ESRD
[4–6].
Medical therapy to address SHPTH has evolved sig-
nificantly over the past decade. Specific changes include
the replacement of aluminum by calcium as the principal
component of phosphate binders, the use of large doses of
oral calcium to suppress PTH, the widespread prescrip-
tion of intravenous vitamin D with hemodialysis, and the
emergence of non–calcium-based binding agents [7–9].
The impact of these changes on the parathyroidectomy
(PTX) rate is not known. Examining trends in PTX rates
over time is complicated by the fact that changes in PTX
rates may be due to changes in medical care, changes in
patient characteristics, or both.
Significantly higher PTX rates have been reported
among younger, nondiabetic ESRD patients, as well as
those with a longer cumulative dialysis duration [10].
Such findings support clinical evidence relating diabetes
and advancing age to the low turnover bone lesion, which
is characterized by diminished circulating PTH levels
[11]. Clinical factors associated with PTX rates among
United States dialysis patients have not been described.
The objectives of the present study are to examine tem-
poral changes in PTX rates among United States dialysis
patients and to describe PTX rates among clinical sub-
groups of dialysis patients. Data from the United States
Renal Database System (USRDS) were used to address
these objectives.
METHODS
Patient population
We utilized patient data from the USRDS, which col-
lects clinical, demographic, and dialysis information for
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all patients receiving chronic renal replacement therapy
in the United States. Details of the USRDS are described
elsewhere [12]. Patients were considered for analysis if
they were at least 18 years old and were receiving renal
replacement therapy between January 1, 1990, and De-
cember 31, 1999. Patients who died, or underwent renal
transplantation or PTX during the first 90 days of dial-
ysis were excluded. The exclusion of the first 90 days of
dialysis time is due to potential delay of the Medicare eli-
gibility application process. Prevalent ESRD patients en-
tering the study on January 1, 1990 were excluded if they
were found to have previously undergone renal trans-
plantation or PTX. Because USRDS hospitalization data
is sourced from Medicare inpatient claims, the study co-
hort was further restricted to patients with fee-for-service
Medicare Part A as their primary payer 90 days after the
start of dialysis (as determined by the USRDS payer his-
tory file).
Data collection
The USRDS obtains data from the Centers for Medi-
care & Medicaid Services (CMS), which accrues de-
mographic, diagnosis, and treatment information for all
Medicare beneficiaries with ESRD. A person is identified
as having ESRD when a physician certifies the disease on
the CMS Medical Evidence form #2728, or when there is
other evidence that a person has received chronic dialysis
or a renal transplant. Transplantation data are obtained
by the USRDS from the United Network for Organ Ser-
vices (UNOS).
Determination of parathyroidectomy
PTX was defined by the occurrence of the International
Classification of Diseases-Clinical Modification (ICD9-
CM) hospital procedure codes 06.81 “Total parathy-
roidectomy” or 06.89 “Other parathyroidectomy.” The
USRDS obtains hospital procedure codes through Medi-
care institutional inpatient claims sourced from CMS.
For each hospitalization, up to 10 procedure codes were
analyzed. Hospitalization data were analyzed through
December 31, 1999.
Determination of risk time
Incident ESRD patients were considered at risk be-
ginning 90 days after the initiation of dialysis. Prevalent
ESRD patients as of January 1, 1990 were considered
at risk beginning on January 1, 1990. All patients were
followed until the first occurrence of death, renal trans-
plantation, loss to follow-up, or PTX. Dates of death are
obtained by the USRDS from CMS form #2746, which
is completed by the primary nephrologist following the
death of any dialysis patient. Loss to follow-up is deter-
mined by the USRDS if there is an absence of dialysis
billing claims for one consecutive year without a noti-
fication of death. For patients determined to be lost to
follow-up, the last date of active dialysis billing was con-
sidered the last date of follow-up. Survival and follow-up
status data were completed through the end of the study.
Statistical analysis
To determine prevalence, patients were not censored at
PTX, and a cross section of all eligible ESRD patients was
ascertained at three specific time points: the study start
(January 1, 1990), mid-point (January 1, 1995), and study
end (December 31, 1999). From these populations, the
proportion of patients who had received a previous PTX
was determined. A binomial distribution of prevalence
was assumed to estimate the variance and corresponding
95% CI.
The incidence rate of PTX was defined as the num-
ber of patients receiving a first PTX during a given time
period divided by the number of person-years at risk dur-
ing that time period. PTX rates were stratified by patient
characteristics. A Poisson distribution of incident rates
was assumed to estimate the variance and corresponding
95% CI.
Multivariate Poisson regression [13] was employed to
estimate the independent relationship between each co-
variate of interest and the proportionate change in the
incident PTX rate. In the Poisson models, the log of
the mean PTX rate was modeled as a function of the
predictor covariates and the resulting coefficients were
transformed into incidence-rate ratios. Time invariant
variables in the multivariate models were age, race, gen-
der, and the primary cause of ESRD. Time-dependent
variables (updated during follow-up) were calendar year
(1990 through 1999), modality (hemodialysis, peritoneal
dialysis), and cumulative dialysis duration (less than
1 year, 1–3 years, greater than 3 years). Interactions be-
tween dialysis duration and each covariate except calen-
dar year were modeled. To estimate adjusted PTX rates,
mean age at study start, race, gender, modality, dialy-
sis duration, and primary renal disease characteristics of
the 1990 dialysis population were entered as constants
into the multivariate model and combined with the co-
efficient for subsequent calendar years. Thus, “adjusted”
PTX rates for each calendar year represent PTX rates
referenced to the 1990 dialysis population with respect to
each covariate in the model.
Negative binomial models were examined to investi-
gate possible violations of the mean variance relationship
assumed by the Poisson model. Robust variance estima-
tion incorporating clustering on unique patient identifiers
was used to determine 95% CI and P values for the mul-
tivariate Poisson models.
RESULTS
Data were available for 779,734 ESRD patients who
were greater than 18 years old and receiving renal
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Table 1. Demographic data among United States dialysis patients
Calendar year
January 1, 1990 January 1, 1995 December 31, 1999
Number of patientsa 87,982 121,820 155,481
Age years 60.5 (14.7) 62.8 (14.9) 63.4 (15.0)
Race
White 49, 584 (56.4%) 65,662 (54.0%) 82,507 (53.2%)
Black 34,616 (39.4%) 50,144 (41.3%) 62,469 (40.3%)
Asian 2404 (2.8%) 3544 (2.9%) 5320 (3.4%)
Other 1278 (1.5%) 2187 (1.8%) 4827 (3.1%)
Gender
Male 44, 155 (50.2%) 61,520 (50.5%) 80,205 (51.6%)
Time on dialysis
<1 year 25,709 (29.2%) 35,962 (29.5%) 45,626 (29.4%)
1–3 years 30,767 (35.0%) 43,358 (35.6%) 54,388 (35.0%)
>3 years 31,506 (35.8%) 42,500 (34.9%) 55,467 (35.7%)
Modality
Hemodialysis 73,533 (86.9%) 102,332 (87.2%) 140,172 (91.8%)
Cause of ESRD
Diabetes 22,580 (25.7%) 39,867 (32.7%) 63,394 (40.8%)
Hypertension 25,824 (29.4%) 38,663 (31.7%) 45,782 (29.5%)
Glomerulonephritis 12,864 (14.6%) 14,494 (11.9%) 16,490 (10.6%)
Polycystic kidney disease 3946 (4.5%) 3662 (3.0%) 3993 (2.6%)
Other/unknown 22,768 (25.9%) 25,134 (20.6%) 25,822 (16.6%)
Values are expressed as mean (sd) or n (%).
aCross-sectional determination of number of patients alive at single time point.
replacement therapy between January 1, 1990, and De-
cember 31, 1999. Patients were excluded if they had re-
ceived a renal transplant (N = 28,615, 3.7%) or a PTX
(N = 626, 0.1%) within the first 90 days of dialysis. Fur-
thermore, prevalent ESRD patients entering the study on
January 1, 1990 were excluded if they were found to have
had a previous renal transplant (N = 31,529, 4.0%) or a
PTX (N = 3196, 0.4%), as determined by USRSD hos-
pitalization and treatment modality data prior to 1990.
Finally, 197,436 (25.3%) patients were excluded because
they were not receiving fee-for-service Medicare insur-
ance as their primary payer 90 days after the initiation of
dialysis. Following these exclusions, 518,332 patients were
available for analysis. Patients whose primary payer was
Medicare tended to be older than those with other insur-
ance; however, other baseline characteristics were similar
among patients covered by Medicare or Medicaid and pa-
tients excluded from study on the basis of other insurance
coverage.
Compared with the dialysis population in 1990, the
dialysis population in 1999 was older and consisted of a
higher proportion of diabetic patients (Table 1). Further-
more, the proportion of hemodialysis patients increased
moderately during the course of the study. The preva-
lence of ESRD patients with a history of PTX at the be-
ginning, mid-point, and study end was 3.5%, 3.3%, and
2.6%, respectively.
We identified 8492 incident PTXs during 1,185,000
person-years of follow-up. The overall PTX rate from
1990 to 1999 was 7.16 incident PTXs per 1000 person-
years at risk (95% CI: 7.01–7.32). The mean cumulative
dialysis duration at the time of first PTX was 5.3 years (in-
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Fig. 1. Crude and adjusted PTX rates per 1000 person-years, adjusted
to patient characteristics as of 1990 with respect to age, race, gender,
cause of ESRD, dialysis modality, and dialysis duration.
terquartile range 2.6, 4.6, and 7.2 years). Adjusted PTX
rates rose slightly between 1990 and 1995, and then de-
clined sharply (Fig. 1, Table 2). By 1999, the adjusted
PTX rate had fallen by approximately 30% as compared
to PTX rates prior to 1995. Adjusted PTX rates for calen-
dar years 1996 to 1999 were significantly lower than the
1990 PTX rate (P = 0.002 for year 1996, P < 0.001 for
years 1997 to 1999).
PTX rates varied substantially across subgroups of dial-
ysis patients (Table 3). After simultaneous adjustment
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Table 2. PTX rates and incidence rate ratios among United States dialysis patients
Calendar Number Unadjusted PTX Unadjusted incidence Adjusted incidence rate
year of PTX ratea (95% CI) rate ratio (95% CI) ratiob (95% CI)
1990 773 8.83 (8.23–9.47) Reference Reference
1991 849 9.05 (8.47–9.68) 1.03 (0.93–1.13) 1.04 (0.94–1.16)
1992 881 8.69 (8.14–9.29) 0.98 (0.89–1.09) 1.05 (0.94–1.16)
1993 908 8.37 (7.84–8.93) 0.95 (0.86–1.04) 1.07 (0.96–1.18)
1994 1006 8.77 (8.25–9.33) 0.99 (0.90–1.09) 1.16 (1.05–1.28)
1995 1001 8.20 (7.71–8.73) 0.93 (0.85–1.02) 1.09 (0.98–1.20)
1996 833 6.42 (6.00–6.87) 0.73 (0.66–0.80) 0.85 (0.77–0.95)
1997 757 5.56 (5.18–5.97) 0.63 (0.57–0.70) 0.75 (0.67–0.83)
1998 697 4.88 (4.53–5.26) 0.55 (0.50–0.61) 0.67 (0.60–0.75)
1999 787 5.29 (4.93–5.67) 0.60 (0.54–0.66) 0.73 (0.66–0.81)
aNumber of incident PTX per 1000 person-years at risk.
bAdjusted for age, race, gender, dialysis modality, dialysis duration, and primary cause of ESRD.
Table 3. PTX rates among United States dialysis patients by patient characteristics
Number of PTX Unadjusted PTX ratea (95% CI) Adjusted incidence rate ratiob (95% CI) P value
Age years
>70 479 1.4 (1.3–1.5) Reference
55–70 2104 4.7 (4.5–4.9) 3.0 (2.7–3.0) <0.001
40–55 2703 11.3 (10.9–11.8) 6.6 (5.9–7.3) <0.001
18–40 3206 21.1 (20.4–21.9) 11.2 (10.1–12.4) <0.001
Race
White 3999 6.2 (6.0–6.4) Reference
Black 4152 8.7 (8.5–9.0) 0.9 (0.9–0.9) <0.001
Asian 225 6.3 (5.5–7.2) 0.8 (0.7–0.9) <0.001
Other 102 3.7 (3.1–4.5) 0.6 (0.5–0.7) <0.001
Gender
Male 3637 6.0 (5.8–6.2) Reference
Female 4855 8.4 (8.1–8.6) 1.6 (1.5–1.7) <0.001
Time on dialysis years
<1 656 1.8 (1.7–2.0) Reference
1–3 1953 4.6 (4.4–4.8) 2.3 (2.1–2.6) <0.001
>3 5880 14.8 (14.5–15.2) 5.9 (5.4–6.4) <0.001
Modality
Hemodialysis 6641 6.7 (6.5–6.8) Reference
Peritoneal dialysis 1512 10.8 (10.3–11.4) 1.4 (1.3–1.4) <0.001
Cause of ESRD
Diabetes 1268 3.1 (2.9–3.2) Reference
Hypertension 2652 7.3 (7.0–7.6) 2.3 (2.1–2.4) <0.001
Glomerulonephritis 1813 13.2 (12.6–13.8) 2.6 (2.4–2.8) <0.001
Polycystic kidney disease 522 15.2 (14.0–16.6) 3.0 (2.7–3.4) <0.001
Other/unknown 1644 9.2 (8.8–9.6) 2.0 (1.9–2.2) <0.001
aNumber of incident PTX per 1000 person-years at risk.
bAdjusted for all of the covariates in the table and calendar year.
for patient characteristics, decreasing age, female gender,
white race, nondiabetic causes of ESRD, peritoneal dial-
ysis, and increasing dialysis duration were found to be
independently associated with increased PTX rates. The
associations for age and dialysis duration were particu-
larly strong.
The absolute impact of age and cause of ESRD on
the PTX rate was influenced by the duration of dialysis
(Table 4). On average, an additional 34.9 PTXs per 1000
person-years were performed among patients younger
than 40 years old receiving dialysis for greater than 3 years
as compared to patients greater than 70 years old receiv-
ing dialysis for less than 1 year. Approximately 10.7 to 12.9
additional PTXs per 1000 person-years were performed
among nondiabetic patients receiving dialysis for greater
than 3 years as compared to diabetic patients receiving
dialysis for less than 1 year.
Finally, we examined PTX rates by geographic region.
Overall, crude PTX rates tended to be slightly higher in
the southeastern United States; however, the decline in
PTX rates over time was consistent across all geographic
regions.
DISCUSSION
Our principal finding is that in the late 1990s, PTX rates
decreased in the United States, independent of changes
in patient characteristics. Further, we found decreasing
age, female gender, nondiabetic causes of renal disease,
longer dialysis duration, and peritoneal dialysis to be in-
dependently associated with higher PTX rates.
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Table 4. Adjusted PTX rates according to dialysis durationa
Time on dialysis
<1 year 1–3 years >3 years
Adjusted rates per 1000 person-years
Age years
>70 0.9 (0.8–1.1)b 1.2 (1.0–1.6) 2.3 (1.8–2.9)
55–70 2.2 (1.7–2.7) 3.8 (3.1–4.7) 8.3 (6.9–10.1)
40–55 2.6 (2.0–3.3) 7.7 (6.3–9.4) 20.6 (17.0–24.9)
18–40 3.6 (2.8–4.6) 13.0 (10.7–15.9) 35.8 (29.6–43.2)
Race
White 2.0 (1.8–2.2)b 4.2 (3.7–4.7) 9.0 (8.1–10.0)
Black 1.1 (0.9–1.3) 3.2 (2.8–3.6) 9.1 (8.2–10.2)
Asian 0.6 (0.3–1.2) 1.7 (1.2–2.5) 8.5 (7.2–10.2)
Other 0.9 (0.5–1.8) 1.9 (1.3–3.0) 5.8 (4.4–7.6)
Gender
Male 1.1 (1.0–1.3)b 3.4 (2.9–3.9) 9.8 (8.5–11.4)
Female 3.1 (2.6–3.7) 6.3 (5.4–7.3) 14.2 (12.3–16.4)
Modality
Hemodialysis 1.0 (1.4–1.7)b 3.7 (3.3–4.1) 9.9 (9.0–10.9)
Peritoneal dialysis 2.6 (2.2–3.1) 5.9 (5.2–6.8) 11.8 (10.6–13.3)
Cause of ESRD
Diabetes 1.6 (0.8–1.2)b 2.4 (2.0–2.9) 5.9 (4.9–7.1)
Hypertension 2.4 (2.4–3.0) 4.8 (4.0–5.8) 13.9 (11.7–17.4)
Glomerulonephritis 2.2 (1.7–2.8) 6.4 (5.2–7.7) 15.4 (12.9–18.4)
Polycystic kidney disease 2.9 (1.9–4.4) 9.0 (7.0–11.5) 16.9 (14.0–20.6)
Other/unknown 2.2 (1.8–2.8) 4.9 (4.0–6.0) 11.7 (9.8–14.0)
aAdjusted to the mean covariate values of each reference group.
bIndicates reference group.
We observed an overall PTX incidence rate of 7.2 per
1000 person-years among our United States dialysis pa-
tient cohort. This rate is slightly higher than the rate of
5.3 per 1000 person-years reported from the Lombardy
Registry of Dialysis and Transplantation [10]. One factor
that may be contributing to the difference is our exclusion
of the first 90 days of dialysis time, in which PTX rates
are extremely low.
In contrast, higher PTX rates have been reported from
studies conducted prior to 1990 [14–16]. The European
Dialysis and Transplant Association reported a PTX in-
cidence rate of 12.1 per 1000 person-years among chronic
dialysis patients in 1982 [14]. The Okinawa dialysis reg-
istry reported PTX incidence rates of 4.2 and 15.2 per 1000
person-years among diabetic and nondiabetic ESRD pa-
tients, respectively, from 1971 to 1990 [15]. These PTX
rates are higher than those we observed of 3.1 and 9.3
per 1000 person-years among diabetic and nondiabetic
patients, respectively. While it is possible that PTX rates
were higher prior to 1990, differences in patient charac-
teristics between prior and current dialysis populations
preclude direct comparisons of former and current rates.
Based on our data, and those from Lombardy, small dif-
ferences in the proportion of diabetic or older patients,
or in the mean dialysis duration, could result in consid-
erably different observed PTX rates. Furthermore, the
Lombardy study found similar PTX rates among patients
initiating dialysis between 1983 and 1985 and those initi-
ating dialysis between 1990 and 1992.
Although the proportion of older, diabetic patients
among the United States dialysis population has in-
creased over time, changes in these factors did not ac-
count for the whole of the decline in PTX rates, which
fell by approximately 30% in the late 1990s after ad-
justment for patient characteristics. Possible explanations
for the declining PTX rates include improved control of
serum PTH levels via medical and dietary intervention,
increased awareness of SHPTH as a multi system disease,
and changes in referral patterns for PTX.
The most likely therapeutic intervention to have im-
pacted the PTX rate is the widespread use of intravenous
calcitriol, which is highly effective in controlling refrac-
tory SHPTH [8]. While no specific data are available
describing changes in calcitriol prescription rates, the rou-
tine prescription of intravenous calcitriol with hemodial-
ysis roughly correlates with the temporal decline in PTX
rates. Newer agents to control SHPTH, such as parical-
citrol and sevelamer, have additional clinical benefits [17,
18], but were not approved for use in the United States
until 1998. Alternatively, referral patterns for PTX among
patients with refractory SHPTH may be changing. While
the safety of PTX and the symptomatic improvement of
bone pain and pruritis have been reported in surgical case
series [19, 20], long-term outcome data comparing pa-
tients who do or do not undergo PTX are unavailable, as
are specific indications for PTX. The lack of hard outcome
data in combination with the continued promise of novel
medical therapies for SHPTH may have delayed referral
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for PTX. Finally, it is possible that heightened awareness
of the cardiovascular toxicity of disordered calcium, phos-
phate, and PTH metabolism [4, 6, 21, 22] has resulted in a
more frequent dietary counseling for hyperphosphatemia
and more aggressive dosing of oral phosphate binders.
For example, coronary artery calcification has recently
been correlated with oral calcium intake in a cohort of
young ESRD patients [6]. It is possible that aggressive
dosing of oral calcium has suppressed PTH secretion and
retarded the development of parathyroid hyperplasia in-
dependent of treatment with vitamin D.
As reported by Malberti [10], we found crude PTX
rates to be substantially higher among younger, nondi-
abetic ESRD patients. These findings complement pre-
vious work relating advancing age and diabetes to the
low turnover bone lesion, characterized by diminished
serum PTH levels [3, 23–25]. PTH secretion is blunted
in vitro by advanced glycation end products, which ac-
cumulate in aging, and by hyperglycemia per se [26, 27,
28]. Further, nondiabetic patients experience a relatively
long pre-ESRD latency period, which may result in more
refractory SHPTH at the onset of dialysis [29].
Similar to the study in Lombardy [10], we found higher
PTX rates among peritoneal dialysis patients and among
women. The finding of higher PTX rates among peri-
toneal dialysis patients is surprising given the tendency
for PD patients to have improved phosphate clearance,
relative hypoparathyroidism, and adynamic bone disease
[11, 23, 30]. It is possible that PD patients are less likely
to receive intravenous vitamin D than hemodialysis pa-
tients. A recent report from a United States dialysis net-
work single found that only 58% of peritoneal dialysis
patients with serum PTH levels >260 pg/mL were re-
ceiving intravenous calcitriol [31]. Furthermore, while the
absolute number of peritoneal dialysis patients who de-
velop refractory SHPTH may be small, such patients may
be more difficult to manage due to the lack of an avail-
able, consistent intravenous vitamin D dosing schedule.
Finally, it is possible that peritoneal dialysis patients are
different from hemodialysis patients with respect to other
clinical factors not measured in the current analysis. The
finding that female patients were at higher risk of PTX,
after adjustment for confounding variables, is intriguing,
though lacking an apparent mechanism. Women are at
higher risk for primary hyperparathyroidism [32], and fe-
male gender has recently been reported to be an inde-
pendent risk factor for higher serum PTH levels among
chronic dialysis patients [33]. While estrogen may stim-
ulate parathyroid hormone secretion [34], the role of
estrogen in renal-related hyperparathyroid states awaits
further elucidation.
Our study has some limitations. Because the URSDS
obtains hospitalization and procedure data for Medicare
claims, our study cohort was limited to ESRD patients re-
ceiving Medicare as their primary payer at the study start.
Medicare patients tended to be older than patients with
other insurance; however, other baseline characteristics
were found to be similar between patients with Medicare
and those with other insurance. Another limitation of the
present study is the lack of serum PTH data among the
general USRDS patient cohort. Without specific serum
PTH data we cannot determine whether declining PTX
rates are due to lower serum PTH levels among ESRD
patients or due to changes in referral patterns for PTX.
The primary strengths of the present study are the use of
a national ESRD patient sample, independent of partic-
ular region or treatment center, the inclusion of greater
than 8000 incident PTXs in the analyses, and the sepa-
ration of temporal changes in PTX rates from temporal
changes in patient characteristics.
CONCLUSION
PTX rates remained relatively stable in the Unites
States between 1990 and 1995, then declined steadily in
the late 1990s after adjustment for temporal changes in
patient characteristics. The increasing use of intravenous
vitamin D during that time period is the most likely ex-
planation for the decline in PTX rates. Higher PTX rates
were observed among younger, female patients, and pa-
tients with nondiabetic causes of ESRD. Such patients
may warrant particularly aggressive dietary and medical
intervention to reduce elevated serum PTH levels.
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